Who are Switching: Bupropion-SR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AXS-05, Combination Bupropion + NRTs, Nefopam administration and prelevment, bupropion + nicotine gum, bupropion + lozenge, bupropion & Citalopram.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/switching-bupropion-sr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Switching: Bupropion-SR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Switching: Bupropion-SR (Switching: Bupropion-SR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor. Area: Psychiatry.

phase 3 Norepinephrine-dopamine reuptake inhibitor Norepinephrine transporter, Dopamine transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Switching: Bupropion-SR (Switching: Bupropion-SR) — VA Office of Research and Development. Bupropion-SR is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Switching: Bupropion-SR TARGET	Switching: Bupropion-SR	VA Office of Research and Development	phase 3	Norepinephrine-dopamine reuptake inhibitor	Norepinephrine transporter, Dopamine transporter
AXS-05	AXS-05	Axsome Therapeutics, Inc.	marketed	Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor)	Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter
Combination Bupropion + NRTs	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
Nefopam administration and prelevment	Nefopam administration and prelevment	University Hospital, Rouen	marketed	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter
bupropion + nicotine gum	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
bupropion + lozenge	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
bupropion & Citalopram	bupropion & Citalopram	University of Colorado, Denver	marketed	Antidepressant combination (NDRI + SSRI)	Norepinephrine transporter, dopamine transporter, serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor class)

Breath of Life International Pharma Ltd · 1 drug in this class
Hospital Universitario de Canarias · 1 drug in this class
Iowa City Veterans Affairs Medical Center · 1 drug in this class
Pablo Rodríguez del Rio · 1 drug in this class
Pfizer · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switching: Bupropion-SR — Competitive Intelligence Brief. https://druglandscape.com/ci/switching-bupropion-sr. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing